Radical prostatectomy for the patient with locally advanced prostate cancer

Current Urology Reports

Volumn 4, Issue 3, 2003, Pages 196-204

  Ward, John F ^a   Zincke, Horst ^a  

^a DEPARTMENT OF UROLOGY   (United States)

Author keywords

Advanced Prostate Cancer; Localize Prostate Cancer; Prostate Cancer; Radiat Oncol Biol Phys; Radical Prostatectomy

Indexed keywords

ADENOCARCINOMA; HOSPITALIZATION; HUMAN; LYMPH NODE METASTASIS; MALE; MORTALITY; PROSTATE TUMOR; REVIEW; SURVIVAL RATE; TIME;

ADENOCARCINOMA; HUMANS; LYMPHATIC METASTASIS; MALE; PROSTATIC NEOPLASMS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TIME FACTORS;

EID: 0041408692     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-003-0069-0     Document Type: Article

References (62)

1. Stanford J, Stephenson R, Coyle L, et al.: Prostate Cancer Trends, 1973–1995. Bethesda: NIH Pub No 99-4543; 1999.
2. Stephenson RA: Prostate cancer trends in the era of prostatespecific antigen: an update of incidence, mortality, and clinical factors from the SEER database. Urol Clin North Am 2002, 29:173–181. DOI: 10.1016/S0094-0143(02)00002-2
3. Cheng L, Zincke H, Blute ML, et al.: Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer 2001, 91:66–73. Combination radical prostatectomy and immediate hormonal therapy in patients with micrometastatic lymph node involvement provides progression-free and cancer-specific survival rates statistically similar to patients without lymph node involvement in a multivariate setting, which controls for other pathologic variables. Micrometastatic disease within the lymph nodes on frozen section examination during planned radical prostatectomy should not be the reason for abandoning prostate extirpation. DOI: 10.1002/1097-0142(20010101)91:1<66::AID-CNCR9>3.0.CO;2-P
4. Zincke H, Fleming TR, Furlow WL, et al.: Radical retropubic prostatectomy and pelvic lymphadenectomy for high-stage cancer of the prostate. Cancer 1981, 47:1901–1910. DOI: 10.1002/1097-0142(19810401)47:7<1901::AID-CNCR2820470731>3.0.CO;2-N
5. Zincke H, Utz DC, Taylor WF: Bilateral pelvic lymphadenectomy and radical prostatectomy for clinical stage C prostatic cancer: role of adjuvant treatment for residual cancer and in disease progression. J Urol 1986, 135:1199–1205.
6. Morgan WR, Bergstralh EJ, Zincke H: Long-term evaluation of radical prostatectomy as treatment for clinical stage C (T3) prostate cancer [comment]. Urology 1993, 41:113–120. DOI: 10.1016/0090-4295(93)90159-8
7. Lerner SE, Blute ML, Zincke H: Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: outcome and contemporary morbidity. J Urol 1995, 154:1447–1452. DOI: 10.1016/S0022-5347(01)66888-5
8. Amling CL, Leibovich BC, Lerner SE, et al.: Primary surgical therapy for clinical stage T3 adenocarcinoma of the prostate. Semin Urol Oncol 1997, 15:215–221.
9. Barry MJ, Albertsen PC, Bagshaw MA, et al.: Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostactectomy, external beam radiotherapy, or expectant management: a retrospective analysis. Cancer 2001, 91:2302–2314. A retrospective study of the outcomes in men with prostate cancer treated with watchful waiting, radiation therapy, or radical prostatectomy. Using case-control matching and multivariate analysis, this study is the closest we have come to a randomized trial of treatment outcome for men with prostate cancer. DOI: 10.1002/1097-0142(20010615)91:12<2302::AID-CNCR1262>3.0.CO;2-P
10. Amling CL, Blute ML, Lerner SE, et al.: Influence of prostate-specific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice [comment]. Mayo Clin Proc 1998, 73:401–406.
11. Thompson IM: Clinical stage C carcinoma of the prostate. AUA Update 1993, 12:82–87.
12. Meltzer D, Egleston B, Abdalla I: Patterns of prostate cancer treatment by clinical stage and age. Am J Public Health 2001, 91:126–128. Distinct patterns of treatment for newly diagnosed prostate cancer are present within medical practice. Some of these patterns may be based on antiquated ideas regarding the proper management of advanced prostate disease.
13. Catalona WJ: Radical surgery for advanced prostate cancer and for radiation failures [comment]. J Urol 1992, 147:916.
14. Steinberg GD, Walsh PC: Expanding role in the management of patients with adenocarcinoma of the prostate. Prob Urol 1990, 4:408–419.
15. Moul JW: The role of radical surgery in the management of radiation recurrent and large volume prostate cancer. Cancer 1991, 68:1265–1271. DOI: 10.1002/1097-0142(19910915)68:6<1265::AID-CNCR2820680615>3.0.CO;2-G
16. Boxer RJ, Kaufman JJ, Goodwin WE: Radical prostatectomy for carcinoma of the prostate 1951–1976: a review of 329 patients. J Urol 1977, 117:208–213.
17. Elder JS, Jewett HJ, Walsh PC: Radical perineal prostatectomy for clinical stage B2 carcinoma of the prostate. J Urol 1982, 127:704–706.
18. Fuks Z, Leibel SA, Wallner KE, et al.: The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125I implantation. Int J Radiat Oncol Biol Phys 1991, 21:537–547.
19. Zagars GK, von Eschenbach AC, Ayala AG, et al.: The influence of local control on metastatic dissemination of prostate cancer treated by external beam megavoltage radiation therapy. Cancer 1991, 68:2370–2377. DOI: 10.1002/1097-0142(19911201)68:11<2370::AID-CNCR2820681107>3.0.CO;2-T
20. Kuban DA, el-Mahdi AM, Schellhammer PF: Effect of local tumor control on distant metastasis and survival in prostatic adenocarcinoma. Urology 1987, 30:420–426. DOI: 10.1016/0090-4295(87)90372-4
21. Tomlinson RL, Currie DP, Boyce WH: Radical prostatectomy: palliation for stage C carcinoma of the prostate. J Urol 1977, 117:85–87.
22. Paulson DF, Hodge GB Jr, Hinshaw W: Radiation therapy versus delayed androgen deprivation for stage C carcinoma of the prostate. J Urol 1984, 131:901–902.
23. de Vere White R, Paulson DF, Glenn JF: The clinical spectrum of prostate cancer. J Urol 1977, 117:323–327.
24. Pavone-Macaluso M, de Voogt HJ, Viggiano G, et al.:Comparison of diethylstilbestrol, cyproterone acetate, and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group. J Urol 1986, 136:624–631.
25. Bagshaw MA, Cox RS, Ray GR: Status of radiation treatment of prostate cancer at Stanford University. NCI Monogr 1988, 7:47–60.
26. Leibel SA, Fuks Z, Zelefsky MJ, Whitmore WF Jr: The effects of local and regional treatment on the metastatic outcome in prostatic carcinoma with pelvic lymph node involvement [comment]. Int J Radiat Oncol Biol Phys 1994, 28:7–16.
27. Kaplan ID, Prestidge BR, Bagshaw MA, Cox RS: The importance of local control in the treatment of prostatic cancer. J Urol 1992, 147:917–921.
28. Coen JJ, Zietman AL, Thakral H, Shipley WU: Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases [see comments]. J Clin Oncol 2002, 20:3199–3205. Examined 1469 patients who were receiving external beam radiotherapy with a curative intent for adenocarcinoma of the prostate. Failure to control the cancer locally was the strongest predictor of distant metastasis. More than two thirds of the patients with clinical locally advanced prostate cancer at treatment fail locally and progress more rapidly distally. There is danger in failing to control the locally advanced prostate cancer with radiotherapy. DOI: 10.1200/JCO.2002.01.086
29. Zietman AL, Westgeest JC, Shipley WU: Radiation-based approaches to the management of T3 prostate cancer. Semin Urol Oncol 1997, 15:230–238.
30. Crook JM, Perry GA, Robertson S, Esche BA: Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients [comment]. Urology 1995, 45:624–631. DOI: 10.1016/S0090-4295(99)80054-5
31. Dugan TC, Shipley WU, Young RH, et al.: Biopsy after external beam radiation therapy for adenocarcinoma of the prostate: correlation with original histological grade and current prostate specific antigen levels [comment]. J Urol 1991, 146:1313–1316.
32. Laverdiere J, Gomez JL, Cusan L, et al.: Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer [comment]. Int J Radiat Oncol Biol Phys 1997, 37:247–252. DOI: 10.1016/S0360-3016(96)00513-5
33. Bolla M, Gonzalez D, Warde P, et al.: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997, 337:295–300. DOI: 10.1056/NEJM199707313370502
34. Zincke H, Bergstralh EJ, Blute ML, et al.: Radical prostatectomy for clinically localized prostate cancer: long-term results of 1,143 patients from a single institution [comment]. J Clin Oncol 1994, 12:2254–2263.
35. Padula GD, Zelefsky MJ, Venkatraman ES, et al.: Normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer [comment]. International J Radiat Oncol Biol Phys 2002, 52:439–443. DOI: 10.1016/S0360-3016(01)02604-9
36. Pilepich MV, Winter K, John MJ, et al.: Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. International J Radiat Oncol Biol Phys 2001, 50:1243–1252. Combination radiotherapy and hormonal therapy does not effectively control high-grade/high-volume prostate cancer locally or at distant sites. Few patients with cT3 prostate cancer have low-grade/ low-volume prostate cancer, which appears to respond to this form of multimodality therapy. DOI: 10.1016/S0360-3016(01)01579-6
37. Kuban DA, el-Mahdi AM, Schellhammer PF: Prognosis in patients with local recurrence after definitive irradiation for prostatic carcinoma. Cancer 1989, 63:2421–2425. DOI: 10.1002/1097-0142(19890615)63:12<2421::AID-CNCR2820631208>3.0.CO;2-1
38. Koprowski CD, Berkenstock KG, Borofski AM, et al.: External beam irradiation versus 125 iodine implant in the definitive treatment of prostate carcinoma [comment]. Int J Radiat Oncol Biol Phys 1991, 21:955–960.
39. Scardino PT: Is radiotherapy effective for locally advanced (stage C or T3) prostate cancer? Prog Clin Biol Res 1989, 303:223–239.
40. Whitmore WF Jr, Hilaris B, Sogani P, et al.: Interstitial irradiation using I-125 seeds. Prog Clin Biol Res 1987, 243B:177–195.
41. Holzman M, Carlton CE Jr, Scardino PT: The frequency and morbidity of local tumor recurrence after definitive radiotherapy for stage C prostate cancer. J Urol 1991, 146:1578–1582.
42. Partin AW, Kattan MW, Subong EN, et al.: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update [erratum appears in JAMA 1997, 278:118]. JAMA 1997, 277:1445–1451. DOI: 10.1001/jama.277.18.1445
43. Yamada AH, Lieskovsky G, Petrovich Z, et al.: Results of radical prostatectomy and adjuvant therapy in the management of locally advanced, clinical stage TC, prostate cancer. Am J Clin Oncol 1994, 17:277–285. DOI: 10.1097/00000421-199408000-00001
44. van den Ouden D, Hop WC, Schroder FH: Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol 1998, 160:1392–1397. Radical prostatectomy as monotherapy in patients with locally advanced nonmetastatic prostate cancer (T3) produces acceptable results in those with well or moderately differentiated tumors. The results of progression and survival are not significantly different from those in patients with locally confined prostate cancer. However, patients with poorly differentiated tumors (T3G3) have early progression and need adjuvant treatment after surgery. DOI: 10.1016/S0022-5347(01)62546-1
45. Zincke H, Lau W, Bergstralh E, Blute ML: Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer. J Urol 2001, 166:2208–2215. Early adjuvant hormonal therapy has a significant impact on time to progression and cause-specific survival in patients with locally advanced prostate cancer after radical prostatectomy. This improvement continues to be observed, even in the very high-risk categories of seinal vesical invasion or limited lymph node metastasis. DOI: 10.1016/S0022-5347(05)65536-X
46. Morgan WR, Zincke H, Rainwater LM, et al.: Prostate-specific antigen values after radical retropubic prostatectomy for adenocarcinoma of the prostate: impact of adjuvant treatment (hormonal and radiation)[comment]. J Urol 1991, 145:319–323.
47. Stein A, deKernion JB, Dorey F, Smith RB: Adjuvant radiotherapy in patients post-radical prostatectomy with tumor extending through capsule or positive seminal vesicles. Urology 1992, 39:59–62. DOI: 10.1016/0090-4295(92)90043-V
48. Schild SE, Wong WW, Grado GL, et al.: The result of radical retropubic prostatectomy and adjuvant therapy for pathologic stage C prostate cancer [comment]. Int J Radiat Oncol Biol Phys 1996, 34:535–541. Low-dose adjuvant radiotherapy after radical prostatectomy improves freedom from recurrence rates for patients with direct local extension of the cancer. When the seminal vesicles are involved with prostate cancer, radiotherapy does not seem to alter disease outcome. DOI: 10.1016/0360-3016(95)02161-2
49. Oesterling JE, Andrews PE, Suman VJ, et al.: Preoperative androgen deprivation therapy: artificial lowering of serum prostate-specific antigen without downstaging the tumor. J Urol 1993, 149:779–782.
50. Van Poppel H, De Ridder D, Elgamal AA, et al.: Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial: The Belgian Uro-Oncological Study Group. J Urol 1995, 154:429–434. DOI: 10.1097/00005392-199508000-00027
51. Andros EA, Danesghari F, Crawford ED: Neoadjuvant hormonal therapy in stage C adenocarcinoma of the prostate. Clin Invest Med 1993, 16:510–515.
52. Aprikian AG, Fair WR, Reuter VE, et al.: Experience with neoadjuvant diethylstilboestrol and radical prostatectomy in patients with locally advanced prostate cancer. Br J Urol 1994, 74:630–636. DOI: 10.1111/j.1464-410X.1994.tb09196.x
53. Armas OA, Aprikian AG, Melamed J, et al.: Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am J Surg Pathol 1994, 18:979–991. DOI: 10.1097/00000478-199410000-00002
54. Sassine AM, Schulman CC: Neoadjuvant hormonal deprivation before radical prostatectomy. Eur Urol 1993, 24(suppl 2):46–50.
55. Schulman CC, Debruyne FM, Forster G, et al.: 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer: European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol 2000, 38:706–713. A prospective, randomized trial of neoadjuvant hormonal therapy followed by radical prostatectomy in all patients (cT2 and cT3) with newly diagnosed prostate cancer. There is no substantial benefit received from neoadjuvant therapy in achieving complete tumor excision, decreased positive surgical margins, or a long-term disease-free interval. DOI: 10.1159/000020366
56. Amling CL, Blute ML, Bergstralh EJ, et al.: Preoperative androgen-deprivation therapy for clinical stage T3 prostate cancer. Semin Urol Oncol 1997, 15:222–229.
57. Petrovich Z, Lieskovsky G, Langholz B, et al.: Comparison of outcomes of radical prostatectomy with and without adjuvant pelvic irradiation in patients with pathologic stage C (T3N0) adenocarcinoma of the prostate. Am J Clin Oncol 1999, 22:323–331. Low-dose postoperative radiotherapy is of low toxicity and it did not increase the incidence of incontinence after radical prostatectomy. In multivariate analysis, patients receiving surgery plus radiotherapy had a significantly lower rate of recurrence than patients undergoing surgery alone, especially for patients with poor prognostic factors. DOI: 10.1097/00000421-199908000-00001
58. Petrovich Z, Lieskovsky G, Langholz B, et al.: Radical prostatectomy and postoperative irradiation in patients with pathological stage C (T3) carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1998, 40:139–147. DOI: 10.1016/S0360-3016(97)00488-4
59. Stromberg J, Martinez A, Benson R, et al.: Improved local control and survival for surgically staged patients with locally advanced prostate cancer treated with up-front low dose rate iridium-192 prostate implantation and external beam irradiation. Int J Radiat Oncol Biol Phys 1994, 28:67–75.
60. Zincke H: Combined surgery and immediate adjuvant hormonal treatment for stage D1 adenocarcinoma of the prostate: Mayo Clinic experience. Semin Urol 1990, 8:175–183.
61. Zincke H, Utz DC, Thule PM, Taylor WF: Treatment options for patients with stage D1 (T0-3,N1-2,M0) adenocarcinoma of prostate. Urology 1987, 30:307–315. DOI: 10.1016/0090-4295(87)90290-1
62. Iocca A, Zincke H: Management of clinical T3 prostate cancer. AUA Update Series 1999, 18:250–255.